Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021 By Adam Barkay|2021-06-22T13:48:20+00:00June 22nd, 2021|All, EHA 2021|Comments Off on Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021 Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: Adam Barkay Related Posts Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
